Return to search

Xandar Kardian pockets $10m in Series A led by Phoenix

Xandar Kardian, a Toronto-based developer of contactless health monitoring solutions enabled by digital ultra-wide-band radar signal processing, has raised $10 million in Series A financing.

Xandar Kardian, a Toronto-based developer of contactless health monitoring solutions enabled by digital ultra-wide-band radar signal processing, has raised $10 million in Series A financing. Phoenix Venture Partners led the round, with participation from Portfolia Active Aging & Longevity Fund, Taronga Ventures and others. The deal will support the commercial rollout of Xandar Kardian’s healthcare solutions and its further growth.

PRESS RELEASE

TORONTO – (December 14, 2021) – Xandar Kardian, a Toronto-based company that develops contactless health monitoring solutions powered by digital ultra wide-band radar signal processing, has closed a $10 million Series A funding round led by Phoenix Venture Partners, Portfolia Active Aging & Longevity Fund and Taronga Ventures, among other investors.

Xandar Kardian’s XK300 Autonomous Health Monitoring Solution is the world’s first and only commercially available, contact-free, continuous VSM (vital sign monitoring) system that is FDA 510(k) cleared as a class II medical device. By introducing a contactless solution for continuous and autonomous vital sign monitoring, including resting heart rate and respiratory rate, Xandar Kardian is revolutionizing patient monitoring and at-home care through incredibly accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers.

Xandar Kardian’s radar technology is also tremendously beneficial in smart building implementation, providing commercial and public building operators with reliable real-time occupancy measurements for more effective energy optimization versus antiquated PIR (passive infrared) motion sensor systems. With 99.9% accuracy in presence detection and up to 92% in occupancy counting via vital sign measurement, Xandar Kardian technologies enable building automation in real-time. The solution has helped more than 100 properties obtain the highest level of energy efficiency and space utilization data.

“At Xandar Kardian, our goal is to enable predictive and preventive care for people everywhere by leveraging the advanced technologies available today. Our radar-based solutions are the future of healthcare and patient monitoring, allowing providers to take continuous vital sign measurements without any intervention – a true breakthrough that will save lives,” said Sam Yang, CEO and founder of Xandar Kardian. “The funds raised in this financing round will support the commercial rollout of our healthcare solutions and the expansion of our RealTech business in a digital-first era.”

Founded in 2017 as a US Delaware C-Corp with international operations spanning South Korea, Canada and the United States, Xandar Kardian is led by CEO and founder Sam Yang with a mission of deploying reliable and high-accuracy cleantech, smart building and healthcare solutions worldwide.

“We’re thrilled to partner with the Xandar Kardian team,” said Zach Jonasson, Co-Founder and Managing General Partner of Phoenix Venture Partners. “Xandar Kardian’s groundbreaking technology and visionary team are well-positioned to enable truly frictionless and actionable health monitoring in healthcare facilities and at home.”

“The Xandar Kardian team has built a credible, world-class technology that can improve safety, health outcomes, and costs, particularly for aging and other vulnerable populations,” said Dr. Christina Jenkins, Venture Partner at Phoenix Venture Partners and Portfolia. “We’re excited to support them in developing predictive capabilities that can help keep people healthy, wherever they are.”

“For nearly a decade, Xandar Kardian has worked to advance digital radar signal processing, using such findings to introduce an essential medical-grade monitoring solution. We look forward to partnering with Sam and the team as this unique technology continues to make a positive impact across healthcare and built environment assets,” said Avi Naidu, Co-Founder & Managing Director at Taronga Ventures.

The Xandar Kardian XK300 Autonomous Health Monitoring Solution achieved 510(k) Clearance by the U.S. Food & Drug Administration in April 2021, paving the way for a new era of accurate and reliable healthcare technology. With 23 patents granted and 11 pending, Xandar Kardian received significant validation at CES 2021 with its XK300 Autonomous Health Monitoring Solution chosen as a recipient of the CES Innovation Award, a prestigious annual competition honoring outstanding design and engineering in consumer technology products.

To learn more about Xandar Kardian and its radar-powered monitoring solutions, visit the Xandar Kardian website at www.xkcorp.com.

About Xandar Kardian
Xandar Kardian is a US Delaware C-Corp with international operations spanning South Korea, Canada, and the United States, focused on deploying reliable and high accuracy security, cleantech and healthcare solutions worldwide. Xandar Kardian elevates motion sensor technology to the next level, incorporating radar sensors that monitor vital signs via resting heart rate (RHR) and respiratory rate (RR), providing essential insights into occupant motion, location, and vital sign reading. Founded in 2017, the team behind Xandar Kardian is focused on digital radar signal processing from start-to-finish, having received FDA 510(k) Clearance for its XK300 in April 2021. For more information, visit www.xkcorp.com.